Fulgent Genetics Inc (FLGT)

Working capital turnover

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Revenue (ttm) US$ in thousands 289,213 286,412 307,380 364,868 618,968 802,935 925,148 953,423 992,584 1,035,891 909,739 773,388 421,712 135,121 43,752 34,911 32,528 29,814 25,092 22,068
Total current assets US$ in thousands 507,845 549,855 528,289 580,723 627,873 696,614 675,185 765,333 611,960 622,836 566,686 659,140 523,616 195,615 41,183 37,025 37,079 39,205 34,795 36,301
Total current liabilities US$ in thousands 73,018 61,421 64,819 81,939 88,107 102,522 127,527 141,714 105,310 147,158 121,524 196,530 130,115 57,736 6,509 5,810 3,723 4,253 2,909 3,203
Working capital turnover 0.67 0.59 0.66 0.73 1.15 1.35 1.69 1.53 1.96 2.18 2.04 1.67 1.07 0.98 1.26 1.12 0.98 0.85 0.79 0.67

December 31, 2023 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $289,213K ÷ ($507,845K – $73,018K)
= 0.67

The working capital turnover of Fulgent Genetics Inc has shown a declining trend over the past year. The ratio has decreased from 1.15 in Q4 of 2022 to 0.67 in Q4 of 2023. This indicates that the company's efficiency in utilizing its working capital to generate revenue has decreased. A lower working capital turnover ratio suggests that the company is struggling to efficiently convert its current assets into sales. Further analysis is needed to understand the reasons behind this decreasing trend and to implement strategies for improvement.


Peer comparison

Dec 31, 2023